三生国健：611（IL-4Rα）项目成人AD适应症临床III期研究中期数据已读出

Core Insights - The company is firmly focused on the autoimmune disease sector as the next major growth area following oncology, emphasizing a clear strategy, differentiated positioning, efficient execution, and open collaboration as key to success [1] - The company employs a three-pronged strategy of "frontier biological insights," a differentiated technology platform, and precise clinical development to drive innovation and clinical advancement [1] Product Development - The company's product 608 (IL-17) demonstrates significant differentiation with advantages such as lower dosing frequency and superior efficacy, showing a PASI100 response rate that outperforms competitors at both 12 weeks and 52 weeks [2] - Current data indicates that product 608 has a low relapse rate, low immunogenicity, and a low incidence of anti-drug antibodies (ADA) with no neutralizing antibodies detected [2] - The company anticipates submitting a New Drug Application (NDA) for product 611 (IL-4Rα) in 2026, as mid-term data from its Phase III clinical study for adult atopic dermatitis shows positive results [2]